Seasonal depression patients now less SAD
Wellbutrin XL (bupropion HCl extended-release tablets) from GlaxoSmithKline has been approved for the prevention of major depressive episodes in patients with a history of seasonal affective disorder (SAD) and is the first drug approved for this indication, the FDA said at a press conference. The depressive episodes associated with SAD can last up to six months and tend to occur during the autumn and winter, when daylight hours are at a minimum.
Seasonal depression patients now less SAD
Wellbutrin XL (bupropion HCl extended-release tablets) from GlaxoSmithKline has been approved for the prevention of major depressive episodes in patients with a history of seasonal affective disorder (SAD) and is the first drug approved for this indication, the FDA said at a press conference. The depressive episodes associated with SAD can last up to six months and tend to occur during the autumn and winter, when daylight hours are at a minimum. The efficacy of Wellbutrin XL was exhibited in three clinical trials in adults with major depressive disorder during the fall and winter months. Treatment was started prior to the onset of symptoms in September and continued through the end of March. At the conclusion of the treatment period, significantly more treated patients were depression-free (84%) than those on placebo (72%).
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
